Enovis Corp (ENOV)

$31.78 -0.48 (-1.49%)
Market Cap 1.84B
Revenue (ttm) 2.11B
Net Income (ttm) -825.49M
EPS (ttm) N/A
PE Ratio 10.23
Forward PE 10.57
Profit Margin -39.17%
Debt to Equity Ratio 0.53
Volume 9,308,000
Avg Vol 1,332,084
Day's Range N/A - N/A
Shares Out 57.12M
Stochastic %K 77%
Beta 1.71
Analysts Strong Sell
Price Target $60.00

Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic sho...

Industry: Medical Devices
Sector: Healthcare
Phone: 302 252 9160
Address:
2711 Centerville Road, Suite 400, Wilmington, United States
DCRMIA
DCRMIA Jun. 6 at 4:36 PM
$ENOV Extremely bullish šŸŽˆšŸŽˆ
0 Ā· Reply
JarvisFlow
JarvisFlow May. 14 at 3:43 PM
Canaccord Genuity updates rating for Enovis ( $ENOV ) to Buy, target set at 75 ā†’ 70.
0 Ā· Reply
JarvisFlow
JarvisFlow May. 9 at 10:30 AM
Needham has updated their rating for Enovis ( $ENOV ) to Buy with a price target of 57.
0 Ā· Reply
LewisDaKat
LewisDaKat May. 8 at 9:55 PM
$ENOV News out Enovis Announces First Quarter 2025 Results https://marketwirenews.com/news-releases/enovis-announces-first-quarter-2025-results-7987892289471101.html $ENOV
0 Ā· Reply
Estimize
Estimize May. 8 at 2:06 PM
$ENOV reported 0.81 EPS and 558.83 revenue for Q1. http://www.estimize.com/intro/enov?chart=historical&metric_name=eps&utm_content=ENOV&utm
0 Ā· Reply
DonCorleone77
DonCorleone77 May. 8 at 10:09 AM
$ENOV Enovis lowers 2025 adjusted EPS view to $2.95-$3.10 from $3.10-$3.25 Consensus for 2025 EPS is $3.18. Raises 2025 revenue view to $$2.22B-$2.25B from $2.19B-$2.22B, consensus $2.21B. Lowers 2025 adjusted EBITDA forecast to $385M-$395M vs. prior outlook of $405M-$415M, and now includes $20M of tariff related impact.
0 Ā· Reply
DonCorleone77
DonCorleone77 May. 8 at 10:05 AM
$ENOV Enovis reports Q1 adjusted EPS 81c, consensus 74c Reports Q1 revenue $559M, consensus $558.9M. "We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations," said CEO Matt Trerotola. "This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment. As we move forward, we remain focused on driving above-market growth through disciplined execution, strategic investment, and a multi-year cadence of high-impact product launches across our portfolio."
0 Ā· Reply
Armonica423
Armonica423 May. 6 at 12:46 PM
$ENOV CYDY
0 Ā· Reply
JarvisFlow
JarvisFlow Apr. 9 at 1:03 PM
Needham updates rating for Enovis ( $ENOV ) to Buy, target set at 64.
0 Ā· Reply
JarvisFlow
JarvisFlow Apr. 2 at 4:12 PM
Needham has updated their rating for Enovis ( $ENOV ) to Buy with a price target of 64.
0 Ā· Reply
Latest News on ENOV
Enovis to Participate in Upcoming Investor Conferences

Jun 6, 2025, 4:05 PM EDT - 21 days ago

Enovis to Participate in Upcoming Investor Conferences

Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor

May 26, 2025, 10:46 AM EDT - 4 weeks ago

Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor

Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript

May 11, 2025, 1:46 AM EDT - 6 weeks ago

Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript

Enovis Announces First Quarter 2025 Results

May 8, 2025, 6:00 AM EDT - 7 weeks ago

Enovis Announces First Quarter 2025 Results

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Apr 17, 2025, 7:00 AM EDT - 2 months ago

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

Apr 2, 2025, 6:30 AM EDT - 3 months ago

Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

Enovisā„¢ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025

Mar 25, 2025, 8:00 AM EDT - 3 months ago

Enovisā„¢ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025

Enovis Continues To Languish Despite Decent Financial Results

Feb 28, 2025, 8:23 AM EST - 4 months ago

Enovis Continues To Languish Despite Decent Financial Results

Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 12:53 PM EST - 4 months ago

Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript

Enovis Announces Fourth Quarter and Full Year 2024 Results

Feb 26, 2025, 6:01 AM EST - 4 months ago

Enovis Announces Fourth Quarter and Full Year 2024 Results

Enovis Announces Planned CEO Succession Process

Feb 26, 2025, 6:00 AM EST - 4 months ago

Enovis Announces Planned CEO Succession Process

Enovisā„¢ Announces Leadership Change to International Surgical Business

Jan 17, 2025, 6:00 AM EST - 5 months ago

Enovisā„¢ Announces Leadership Change to International Surgical Business

Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

Jan 7, 2025, 6:19 PM EST - 6 months ago

Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 6 months ago

Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Enovis Corporation: Reasonably Valued With Caveats

Nov 22, 2024, 12:17 PM EST - 7 months ago

Enovis Corporation: Reasonably Valued With Caveats

Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 12:50 PM EST - 8 months ago

Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript

Enovis Announces Third Quarter 2024 Results

Nov 6, 2024, 6:00 AM EST - 8 months ago

Enovis Announces Third Quarter 2024 Results

Enovis to Host Third Quarter 2024 Results Conference Call on November 6th

Oct 10, 2024, 7:00 AM EDT - 9 months ago

Enovis to Host Third Quarter 2024 Results Conference Call on November 6th

Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says

Oct 3, 2024, 3:39 PM EDT - 9 months ago

Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says

Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Sep 9, 2024, 3:50 PM EDT - 10 months ago

Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWRā„¢ Cones to EMPOWR Revision Kneeā„¢, Creating a Comprehensive Portfolio for Efficient Revision Procedures

Aug 20, 2024, 8:00 AM EDT - 11 months ago

Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWRā„¢ Cones to EMPOWR Revision Kneeā„¢, Creating a Comprehensive Portfolio for Efficient Revision Procedures

Enovisā„¢ Introduces STARĀ® Ankle, now with e+ā„¢ Polyethylene for Unmatched Durability

Aug 19, 2024, 8:00 AM EDT - 11 months ago

Enovisā„¢ Introduces STARĀ® Ankle, now with e+ā„¢ Polyethylene for Unmatched Durability

Enovis Announces Second Quarter 2024 Results

Aug 7, 2024, 6:00 AM EDT - 11 months ago

Enovis Announces Second Quarter 2024 Results

Enovis Announces Time Change for Second Quarter 2024 Results Conference Call

Jul 25, 2024, 6:00 AM EDT - 1 year ago

Enovis Announces Time Change for Second Quarter 2024 Results Conference Call

Enovis to Host Second Quarter 2024 Results Conference Call on August 7th

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Enovis to Host Second Quarter 2024 Results Conference Call on August 7th

Enovis Languishing Despite Respectable Performance

Jul 15, 2024, 12:58 AM EDT - 1 year ago

Enovis Languishing Despite Respectable Performance

Enovisā„¢ Releases AltiVate ReverseĀ® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate ReverseĀ®

Jul 12, 2024, 8:00 AM EDT - 1 year ago

Enovisā„¢ Releases AltiVate ReverseĀ® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate ReverseĀ®

Top 3 Health Care Stocks That Could Blast Off In June

Jun 21, 2024, 8:22 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In June

PEN RGEN

Enovis Corporation (ENOV) Q1 2024 Earnings Call Transcript

May 2, 2024, 2:24 PM EDT - 1 year ago

Enovis Corporation (ENOV) Q1 2024 Earnings Call Transcript

Enovis Announces First Quarter 2024 Results

May 2, 2024, 6:00 AM EDT - 1 year ago

Enovis Announces First Quarter 2024 Results

Enovis to Host First Quarter 2024 Results Conference Call on May 2nd

Apr 17, 2024, 7:00 AM EDT - 1 year ago

Enovis to Host First Quarter 2024 Results Conference Call on May 2nd

Enovis Corporation (ENOV) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 12:14 PM EST - 1 year ago

Enovis Corporation (ENOV) Q4 2023 Earnings Call Transcript

Enovis Announces Fourth Quarter and Full Year 2023 Results

Feb 22, 2024, 6:00 AM EST - 1 year ago

Enovis Announces Fourth Quarter and Full Year 2023 Results

Enovisā„¢ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting

Feb 12, 2024, 11:30 AM EST - 1 year ago

Enovisā„¢ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting

Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

Feb 7, 2024, 4:15 PM EST - 1 year ago

Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

Enovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd

Jan 26, 2024, 6:00 AM EST - 1 year ago

Enovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd

Enovis Introduces the DonJoy ROAMā„¢ OA Knee Brace

Jan 25, 2024, 8:30 AM EST - 1 year ago

Enovis Introduces the DonJoy ROAMā„¢ OA Knee Brace

Enovis Completes Acquisition of LimaCorporate S.p.A

Jan 3, 2024, 6:00 AM EST - 1 year ago

Enovis Completes Acquisition of LimaCorporate S.p.A

Enovis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 28, 2023, 5:00 AM EST - 1 year ago

Enovis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Enovis Announces Business Segment Leadership Transition Plan

Dec 5, 2023, 6:00 AM EST - 1 year ago

Enovis Announces Business Segment Leadership Transition Plan

Enovis to participate in the 6th Annual EverCore ISI HealthCONx Conference

Nov 16, 2023, 4:15 PM EST - 1 year ago

Enovis to participate in the 6th Annual EverCore ISI HealthCONx Conference

Enovis Corporation (ENOV) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:32 AM EST - 1 year ago

Enovis Corporation (ENOV) Q3 2023 Earnings Call Transcript

Enovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook

Nov 7, 2023, 6:00 AM EST - 1 year ago

Enovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook

ENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028

Oct 20, 2023, 6:00 AM EDT - 1 year ago

ENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028

Enovis Corporation Releases Preliminary Information About Its Performance for the Third Quarter 2023

Oct 19, 2023, 6:58 AM EDT - 1 year ago

Enovis Corporation Releases Preliminary Information About Its Performance for the Third Quarter 2023

Enovis Corporation Announces Proposed Private Offering of $400 Million of Convertible Senior Notes

Oct 19, 2023, 6:51 AM EDT - 1 year ago

Enovis Corporation Announces Proposed Private Offering of $400 Million of Convertible Senior Notes

Enovis to Host Third Quarter 2023 Results Conference Call on November 7th

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Enovis to Host Third Quarter 2023 Results Conference Call on November 7th

Enovis Making Good Choices, But Not Seeing The Rewards

Sep 27, 2023, 1:23 PM EDT - 1 year ago

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis to acquire implant maker LimaCorporate for 800 million euros in cash and stock

Sep 25, 2023, 6:14 AM EDT - 1 year ago

Enovis to acquire implant maker LimaCorporate for 800 million euros in cash and stock

Enovis to Acquire LimaCorporate S.p.A.

Sep 25, 2023, 6:00 AM EDT - 1 year ago

Enovis to Acquire LimaCorporate S.p.A.

DCRMIA
DCRMIA Jun. 6 at 4:36 PM
$ENOV Extremely bullish šŸŽˆšŸŽˆ
0 Ā· Reply
JarvisFlow
JarvisFlow May. 14 at 3:43 PM
Canaccord Genuity updates rating for Enovis ( $ENOV ) to Buy, target set at 75 ā†’ 70.
0 Ā· Reply
JarvisFlow
JarvisFlow May. 9 at 10:30 AM
Needham has updated their rating for Enovis ( $ENOV ) to Buy with a price target of 57.
0 Ā· Reply
LewisDaKat
LewisDaKat May. 8 at 9:55 PM
$ENOV News out Enovis Announces First Quarter 2025 Results https://marketwirenews.com/news-releases/enovis-announces-first-quarter-2025-results-7987892289471101.html $ENOV
0 Ā· Reply
Estimize
Estimize May. 8 at 2:06 PM
$ENOV reported 0.81 EPS and 558.83 revenue for Q1. http://www.estimize.com/intro/enov?chart=historical&metric_name=eps&utm_content=ENOV&utm
0 Ā· Reply
DonCorleone77
DonCorleone77 May. 8 at 10:09 AM
$ENOV Enovis lowers 2025 adjusted EPS view to $2.95-$3.10 from $3.10-$3.25 Consensus for 2025 EPS is $3.18. Raises 2025 revenue view to $$2.22B-$2.25B from $2.19B-$2.22B, consensus $2.21B. Lowers 2025 adjusted EBITDA forecast to $385M-$395M vs. prior outlook of $405M-$415M, and now includes $20M of tariff related impact.
0 Ā· Reply
DonCorleone77
DonCorleone77 May. 8 at 10:05 AM
$ENOV Enovis reports Q1 adjusted EPS 81c, consensus 74c Reports Q1 revenue $559M, consensus $558.9M. "We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations," said CEO Matt Trerotola. "This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment. As we move forward, we remain focused on driving above-market growth through disciplined execution, strategic investment, and a multi-year cadence of high-impact product launches across our portfolio."
0 Ā· Reply
Armonica423
Armonica423 May. 6 at 12:46 PM
$ENOV CYDY
0 Ā· Reply
JarvisFlow
JarvisFlow Apr. 9 at 1:03 PM
Needham updates rating for Enovis ( $ENOV ) to Buy, target set at 64.
0 Ā· Reply
JarvisFlow
JarvisFlow Apr. 2 at 4:12 PM
Needham has updated their rating for Enovis ( $ENOV ) to Buy with a price target of 64.
0 Ā· Reply
DonCorleone77
DonCorleone77 Apr. 2 at 10:58 AM
$ENOV $LIVN Enovis names Damien McDonald as CEO, succeeding Matt Trerotola Enovis (ENOV) announced the appointment of Damien McDonald as CEO, effective May 12. McDonald will also join the Enovis Board of Directors following the conclusion of the company's 2025 Annual Meeting of Stockholders on May 21. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova (LIVN).
0 Ā· Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 6:26 PM
$ENOV Digging the Lima acquisition play. Recon segment looking strong with 59% global revenue growth. Eyeing their innovation pipeline - shoulder, knee solutions could be game changers. Might start building a position here. notable article: https://beyondspx.com/article/enovis-corporation-enov-a-steadfast-medtech-leader-driving-innovation-and-growth
0 Ā· Reply
SentimentTraderXX
SentimentTraderXX Mar. 13 at 1:01 PM
$ENOV accumulating
0 Ā· Reply
JarvisFlow
JarvisFlow Feb. 27 at 10:06 AM
Needham updates rating for Enovis ($ENOV) to Buy, target set at 65 ā†’ 64.
0 Ā· Reply
DonCorleone77
DonCorleone77 Feb. 26 at 11:47 AM
$ENOV Enovis sees FY25 adjusted EPS $3.10-$3.25, consensus $3.16 Sees FY25 revenue $2.19B-$2.22B, consensus $2.22B. Adjusted EBITDA is forecasted to be $405M-415M, which represents 60-70 basis points expansion year-over-year.
0 Ā· Reply
DonCorleone77
DonCorleone77 Feb. 26 at 11:41 AM
$ENOV Enovis reports Q4 adjusted EPS 98c, consensus 92c Reports Q4 revenue $561M, consensus $555.14M. "Our performance in 2024 marks a transformational year for the Company as we executed our integration plans and solidified our ability to deliver sustainable high-single-digit organic growth and year-over-year margin expansion," said Matt Trerotola, CEO of Enovis. "Our strong finish in 2024 has set a solid foundation for 2025 with key new product launches positioned to drive above market growth rates."
0 Ā· Reply
Estimize
Estimize Feb. 26 at 11:00 AM
$ENOV reported - EPS and - revenue for Q4. http://www.estimize.com/intro/enov?chart=historical&metric_name=eps&utm_content=ENOV&utm_medium=
0 Ā· Reply
NavaNumbers
NavaNumbers Feb. 19 at 3:09 PM
$VREX $ENOV $STX šŸ”„ M Y N Z šŸš€ Shhhā€¦ PR Expected! Armistice Capital just grabbed 10% stake on MYNZ, Petra teasing MAJOR partnership, FDA resub ahead of schedule & 99% pre-cancer detection locked in! $ 14 PTā€¦ buckle up! šŸš€šŸ”„
0 Ā· Reply
Josin64eBu_an
Josin64eBu_an Feb. 13 at 9:34 AM
$VREX $ENOV $STX šŸ”„ ONEI šŸ”„ Gaming Buzz Confirmed ā€“ Official LinkedIn OneMeta just posted updates on gaming industry initiatives! NYSE uplisting + AI-driven multilingual gaming expansionā€¦ Xbox partnership next?! šŸš€šŸŽ®šŸ”„
0 Ā· Reply
kylevallans
kylevallans Jan. 13 at 7:40 PM
$CART $IJH $IJR $ENOV $ARCH
0 Ā· Reply
tradingcalendar
tradingcalendar Jan. 13 at 7:36 PM
S&P600 and S&P400 index changes today on market close. S&P600 Addition - $ENOV Deletion - $ARCH (Pending Acq by CEIX) S&P400 Addition - $CART Deletion - ENOV $IJH $IJR
0 Ā· Reply